RxDoctor Payments Data

Vinh Nguyen, DO

Cardiovascular Disease · Austin, TXNPI 1306886387

Payments from drug & device makers

$251,737in general payments, 2019–2025

Across 858 payments — averaging $293.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BD$203K
  • Lilly USA, LLC$18K
  • Atricure, Inc.$12K
  • Abbott$8K
  • Johnson & Johnson$2K
  • Novartis$2K
  • plus $8K from 34 others

What the payments were for

  • Consulting fees$14,55030%
  • Speaking & faculty fees$13,69828%
  • Travel & lodging$4561%
  • Food & beverage$20,41341%
  • Education$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$251,737 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$723,845
Medicare patients
2,392
Services billed
10,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban631$752,520
XareltoRivaroxaban517$604,900
JardianceEmpagliflozin339$435,477
EntrestoSacubitril/Valsartan178$204,665
Repatha SureclickEvolocumab126$129,000
MultaqDronedarone Hcl84$119,556
OzempicSemaglutide71$72,956
Ranolazine ErRanolazine187$23,095
Repatha SyringeEvolocumab16$18,681
Nebivolol Hcl217$12,706
Metoprolol Succinate805$11,543
Repatha PushtronexEvolocumab12$11,426
Rosuvastatin Calcium912$10,336
Losartan Potassium822$9,431
VascepaIcosapent Ethyl11$9,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$814$752,520631 claims
Johnson & JohnsonXarelto$1,692$604,900517 claims
Boehringer IngelheimJardiance, Pradaxa$100$437,519350 claims
NovartisEntresto$1,631$204,665178 claims
Sanofi-aventis U.S. LLCMultaq$198$119,55684 claims
Novo NordiskOzempic$1,154$72,95671 claims
AstraZenecaBrilinta$295$7,55616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →